Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Smith-Magenis syndrome (SMS) is described in the packet definition as a complex genetic disorder characterized by variable intellectual deficit, sleep disturbance, craniofacial and skeletal anomalies, psychiatric disorders, and speech and motor delay. Synonyms in the packet include 17p11.2 microdeletion syndrome and chromosome 17p11.2 deletion syndrome. The packet cross-references OMIM:182290, Orphanet:819, GARD:8197, and MESH:D058496, categorizes onset as infantile, and records the ear and nervous system as affected organ systems.
For prevalence, the packet certifies the category uncommon, with an estimate of 1-9 in 100,000. GeneReviews separately states that the birth incidence of SMS is estimated at 1 in 25,000 births and that the actual prevalence may be closer to 1 in 15,000. GeneReviews reports that more than 400 individuals with a deletion or pathogenic variant involving RAI1 have been described, and that features can be subtle in infancy and early childhood, frequently delaying diagnosis until school age.
The packet lists three patient organizations: PRISMS (Parents & Researchers Interested in Smith-Magenis Syndrome), which is recorded as having a registry, the Smith-Magenis Syndrome Foundation, and the Smith-Magenis Syndrome Research Foundation.
The packet records 78 phenotypes in total with frequency labels from the Human Phenotype Ontology. Listed as always present (100%) are intellectual disability, strabismus, square face, truncal obesity, hypotonia, global developmental delay (including mild global developmental delay), and midface retrusion. Listed as very frequent (80-99%) are hoarse voice, malar flattening, self-mutilation, brachydactyly, sleep disturbance, and wide nasal bridge. Listed as frequent (30-79%) are broad face, pain insensitivity, gastroesophageal reflux, pes planus, hearing impairment, abnormality of the dentition, constipation, broad palm, abnormal middle ear morphology, hyperactivity, and abnormality of the outer ear.
GeneReviews describes a clinically recognizable phenotype with physical, developmental, and behavioral features. It lists a broad, square-shaped face, midfacial retrusion, infantile hypotonia, speech-language impairment, inverted circadian sleep rhythm, stereotypic and self-injurious behaviors, and signs of peripheral neuropathy. It reports hearing loss in 79% and hyperacusis in 74% of individuals. Features it places in the 50%-75% range include short stature, scoliosis, ventriculomegaly on brain imaging, ocular abnormalities, hypercholesterolemia, chronic constipation, features of autism spectrum disorder, and low immunoglobulin A. Cardiac defects, thyroid function abnormalities, and seizures (11%-30%) are described as less common.
The only gene listed in the packet for SMS is RAI1, located on chromosome 17, and ClinGen validity is recorded as definitive. The packet lists sporadic and autosomal dominant as inheritance patterns.
GeneReviews states that SMS is an autosomal dominant disorder typically caused by a heterozygous de novo deletion at chromosome 17p11.2 that includes RAI1, or by a heterozygous intragenic RAI1 pathogenic variant. It reports that almost all individuals tested with biological parents have the disorder as a result of a de novo alteration, and that rarely the alteration is inherited from a mosaic parent, results from a parental structural chromosome rearrangement, or is an intragenic RAI1 variant inherited from an affected parent. GeneReviews also notes that parental origin of the 17p deletion has not been documented to affect the phenotype.
GeneReviews describes several genotype-phenotype correlations. Individuals with a deletion including RAI1 are described as more cognitively impaired than those with an intragenic RAI1 variant, with more marked speech delay, and genitourinary anomalies are reported in 15%-35% of those with a deletion but not in those with an RAI1 variant. Higher rates of onychotillomania and polyembolokoilamania (90% compared with 40%) and a higher risk of obesity are reported with RAI1 variants than with deletions.
GeneReviews states that no consensus clinical diagnostic criteria for SMS have been published. It describes the diagnosis as established in a proband by molecular genetic testing identifying either a heterozygous deletion of 17p11.2 that includes RAI1 or a heterozygous pathogenic or likely pathogenic variant involving RAI1, and notes that a heterozygous RAI1 variant of uncertain significance does not establish or rule out the diagnosis. Testing approaches it names include chromosomal microarray analysis, single-gene testing, multigene panels, and exome or genome sequencing.
Clinical findings that GeneReviews lists as suggestive include a subtly distinctive facial appearance that becomes more evident with age, developmental delay or intellectual disability with early speech delay, a distinct neurobehavioral phenotype with self-injurious behaviors, infantile hypotonia, sleep disturbances, childhood-onset obesity, scoliosis, and ophthalmologic and otolaryngologic abnormalities. Laboratory findings listed include an inverted diurnal circadian melatonin rhythm, childhood hyperlipidemia, and immune function abnormalities, especially low immunoglobulin A. Nonspecific brain abnormalities on imaging, including cortical atrophy and ventriculomegaly, are reported in more than 50% of affected individuals.
GeneReviews states that SMS is typically caused by a de novo alteration, so most probands represent a single occurrence in a family. Its differential diagnosis discussion notes that the behavioral features and circadian sleep disorder with inverted melatonin secretion help distinguish SMS from other neurodevelopmental disorders, and that disorders with intellectual disability, including Down syndrome, 22q11.2 deletion syndrome, and Prader-Willi syndrome, share overlapping features.
The packet contains no approved_treatments records for SMS, so no FDA-approved option for this condition is certified in this packet. The orphan drug records in the packet include one designation for melatonin, sponsored by WORPHMED Srl, for treatment of Smith-Magenis syndrome in combination with a beta-blocker; this is a designation status and does not indicate approval. The other orphan records in the packet name unrelated indications and are not described here.
GeneReviews states that there is no cure for SMS and describes supportive care, ideally involving multidisciplinary specialists, aimed at improving quality of life, maximizing function, and reducing complications. For epilepsy, it describes standard treatment with anti-seizure medications and states that none has been demonstrated effective specifically for SMS. For behavioral and psychiatric concerns, it describes structured school programs, behavioral support plans, and developmental psychiatric services, and states that no single medication regimen has been shown to be consistently effective.
For the sleep disorder, GeneReviews discusses melatonin, with early anecdotal reports of variable improvement; tasimelteon, a melatonin receptor agonist, for which a randomized crossover study reported improved sleep quality and total sleep time; a single uncontrolled study of an oral beta-1-adrenergic antagonist; and an uncontrolled trial combining daytime acebutolol with evening melatonin, which reported improved nighttime sleep. Tasimelteon does not appear in the packet's approved_treatments records. GeneReviews also describes dietary changes with portion management for obesity. It notes that weight gain is a concern with many antipsychotics and that some medications may worsen sleep or behavior.
4 trials found
The packet does not certify a prognosis or life expectancy for SMS. GeneReviews describes some natural history features: facial and behavioral features become more recognizable in early childhood, maladaptive behaviors typically begin in early elementary school, atypical sensory processing patterns may become more prominent with age, and in adults keratoconus and glaucoma are seen. GeneReviews does not state an overall outcome in the sections reviewed for this packet.
The packet lists two ClinicalTrials.gov records. NCT05116904, titled Smith Magenis Syndrome and Autism Spectrum Disorders, is a non-applicable-phase study sponsored by Hospices Civils de Lyon, with status recruiting and dates from 2022-03-30 to 2027-04-01. NCT03154697, titled Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances, is sponsored by Vanda Pharmaceuticals, with status recruiting and dates from 2016-01-01 to 2030-12-01. A trial title alone does not establish the intervention studied. The packet's trial intervention summary classifies the intervention type as other interventions.
Data assembled from 10 of 12 sources · Last updated Nov 18, 2026, 8:43 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning Smith-Magenis syndrome
Updated May 24, 2026
A recent study identifies distinct neuropsychiatric profiles linked to 17p11.2 deletions and RAI1 variants in Smith-Magenis Syndrome. This research enhances understanding of the genetic underpinnings of the disorder.